KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK) said that the U.S. Food
and Drug Administration has approved sotatercept-csrk (U.S. Brand Name:
Winrevair, for injection, 45mg, 60mg) for the treatment of adults with pulmonary
arterial hypertension to increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical worsening events.

Winrevair was previously granted Breakthrough Therapy Designation by the FDA.

Pulmonary arterial hypertension is a rare, progressive and ultimately
life-threatening disease in which blood vessels in the lungs thicken and narrow,
causing significant strain on the heart.

Merck warned that Winrevair may increase hemoglobin and may lead to
erythrocytosis, which if severe may increase the risk of thromboembolic events
or hyperviscosity syndrome. Winrevair also may decrease platelet count and lead
to severe thrombocytopenia, which may increase the risk of bleeding;
thrombocytopenia occurred more frequently in patients also receiving
prostacyclin infusion.

The company advises patients not to breastfeed while using Winrevair and for 4
months after completing the final dose due to the risk of serious adverse
reactions in the breastfed child.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX